Search

Your search keyword '"Julia del Amo"' showing total 11 results
Start Over Author "Julia del Amo" Publication Year Range Last 3 years
11 results on '"Julia del Amo"'

1. Epidemiologic Features and Control Measures during Monkeypox Outbreak, Spain, June 2022

Author

Berta Suárez Rodríguez, Bernardo R. Guzmán Herrador, Asunción Díaz Franco, María Paz Sánchez-Seco Fariñas, Julia del Amo Valero, Adrián Hugo Aginagalde Llorente, Juan Pablo Alonso Pérez de Agreda, Rosa Carbó Malonda, Daniel Castrillejo, María Dolores Chirlaque López, Eduardo Javier Chong Chong, Sonia Fernández Balbuena, Virtudes Gallardo García, Manuel García-Cenoz, Laura García Hernández, Elisa Gil Montalbán, Fernando González Carril, Teresa González Cortijo, Susana Jiménez Bueno, Aurora Limia Sánchez, Juan Antonio Linares Dópido, Nicola Lorusso, Mario Margolles Martins, Eva María Martínez Ochoa, Ana Martínez Mateo, Jacobo Mendioroz Peña, Ana Isabel Negredo Antón, María Teresa Otero Barrós, Maria del Carmen Pacheco Martinez, Pilar Peces Jiménez, Oscar-Guillermo Pérez Martín, Ana Isabel Rivas Pérez, María Sastre García, National Monkeypox Response Group, Fernando Simón Soria, and María José Sierra Moros

Subjects
monkeypox, outbreak, multicountry, response, monkeypox viruses, viruses, Medicine, Infectious and parasitic diseases, RC109-216
Abstract

During June 2022, Spain was one of the countries most affected worldwide by a multicountry monkeypox outbreak with chains of transmission without identified links to disease-endemic countries. We provide epidemiologic features of cases reported in Spain and the coordinated measures taken to respond to this outbreak.

Published
2022
Full Text
View/download PDF

2. Global associations of key populations with HIV-1 recombinants: a systematic review, global survey, and individual participant data meta-analysis

Author

Nkazi Nchinda, Ramyiadarsini Elangovan, Jason Yun, Leslie Dickson-Tetteh, Shona Kirtley, Joris Hemelaar, WHO-UNAIDS Network for HIV Isolation and Characterisation, Alash'le G. Abimiku, Simon Agwale, Chris Archibald, Boaz Avidor, Barbás María Gabriela, Francoise Barre-Sinoussi, Banson Barugahare, El Hadj Belabbes, Silvia Bertagnolio, Deborah Birx, Aleksei F. Bobkov, James Brandful, Helba Bredell, Catherine A. Brennan, James Brooks, Marie Bruckova, Luigi Buonaguro, Franco Buonaguro, Stefano Buttò, Anne Buve, Mary Campbell, Jean Carr, Alex Carrera, Manuel Gómez Carrillo, Connie Celum, Beth Chaplin, Macarthur Charles, Dimitrios Chatzidimitriou, Zhiwei Chen, Katsumi Chijiwa, David Cooper, Philip Cunningham, Anoumou Dagnra, Cillian F. de Gascun, Julia Del Amo, Elena Delgado, Ursula Dietrich, Dominic Dwyer, Dennis Ellenberger, Barbara Ensoli, Max Essex, Herve Fleury, Peter N. Fonjungo, Vincent Foulongne, Deepak A. Gadkari, Feng Gao, Federico García, Roger Garsia, Guy Michel Gershy-Damet, Judith R. Glynn, Ruth Goodall, Zehava Grossman, Monick Lindenmeyer Guimarães, Beatrice Hahn, Raph L. Hamers, Osamah Hamouda, Ray Handema, Xiang He, Joshua Herbeck, David D. Ho, Africa Holguin, Mina Hosseinipour, Gillian Hunt, Masahiko Ito, Mohamed Ali Bel Hadj Kacem, Erin Kahle, Pontiano Kaleebu, Marcia Kalish, Adeeba Kamarulzaman, Chun Kang, Phyllis Kanki, Edward Karamov, Jean-Claude Karasi, Kayitesi Kayitenkore, Tony Kelleher, Dwip Kitayaporn, Leondios G. Kostrikis, Claudia Kucherer, Claudia Lara, Thomas Leitner, Kirsi Liitsola, Jai Lingappa, Marek Linka, Ivette Lorenzana de Rivera, Vladimir Lukashov, Shlomo Maayan, Luzia Mayr, Francine McCutchan, Nicolas Meda, Elisabeth Menu, Fred Mhalu, Doreen Mloka, John L. Mokili, Brigitte Montes, Orna Mor, Mariza Morgado, Fausta Mosha, Awatef Moussi, James Mullins, Rafael Najera, Mejda Nasr, Nicaise Ndembi, Joel R. Neilson, Vivek R. Nerurkar, Florian Neuhann, Claudine Nolte, Vlad Novitsky, Philippe Nyambi, Marianna Ofner, Fem J. Paladin, Anna Papa, Jean Pape, Neil Parkin, Chris Parry, Martine Peeters, Alexandra Pelletier, Lucía Pérez-Álvarez, Deenan Pillay, Angie Pinto, Trinh Duy Quang, Cecilia Rademeyer, Filimone Raikanikoda, Mark A. Rayfield, Jean-Marc Reynes, Tobias Rinke de Wit, Kenneth E. Robbins, Morgane Rolland, Christine Rousseau, Jesus Salazar-Gonzales, Hanan Salem, Mika Salminen, Horacio Salomon, Paul Sandstrom, Mario L. Santiago, Abdoulaye D. Sarr, Bryan Schroeder, Michel Segondy, Philippe Selhorst, Sylvester Sempala, Jean Servais, Ansari Shaik, Yiming Shao, Amine Slim, Marcelo A. Soares, Elijah Songok, Debbie Stewart, Julie Stokes, Shambavi Subbarao, Ruengpung Sutthent, Jun Takehisa, Amilcar Tanuri, Kok Keng Tee, Kiran Thapa, Michael Thomson, Tyna Tran, Willy Urassa, Hiroshi Ushijima, Philippe van de Perre, Guido van der Groen, Kristel van Laethem, Joep van Oosterhout, Ard van Sighem, Eric van Wijngaerden, Anne-Mieke Vandamme, Jurgen Vercauteren, Nicole Vidal, Lesley Wallace, Carolyn Williamson, Dawit Wolday, Jianqing Xu, Chunfu Yang, Linqi Zhang, and Rong Zhang

Subjects
HIV, key populations, recombinant, CRF, URF, molecular epidemiology, Public aspects of medicine, RA1-1270
Abstract

IntroductionGlobal HIV infections due to HIV-1 recombinants are increasing and impede prevention and treatment efforts. Key populations suffer most new HIV infections, but their role in the spread of HIV-1 recombinants is unknown. We conducted a global analysis of the associations between key populations and HIV-1 recombinants.MethodsWe searched PubMed, EMBASE, CINAHL, and Global Health for HIV-1 subtyping studies published from 1/1/1990 to 31/12/2015. Unpublished data was collected through a global survey. We included studies with HIV-1 subtyping data of key populations collected during 1990-2015. Key populations assessed were heterosexual people (HET), men who have sex with men (MSM), people who inject drugs (PWID), vertical transmissions (VERT), commercial sex workers (CSW), and transfusion-associated infections (BLOOD). Logistic regression was used to determine associations of key populations with HIV-1 recombinants. Subgroup analyses were performed for circulating recombinant forms (CRFs), unique recombinant forms (URFs), regions, and time periods.ResultsEight hundred and eighty five datasets including 77,284 participants from 83 countries were included. Globally, PWID were associated with the greatest odds of recombinants and CRFs (OR 2.6 [95% CI 2.46–2.74] and 2.99 [2.83–3.16]), compared to HET. CSW were associated with increased odds of recombinants and URFs (1.59 [1.44–1.75] and 3.61 [3.15–4.13]). VERT and BLOOD were associated with decreased odds of recombinants (0.58 [0.54–0.63] and 0.43 [0.33–0.56]). MSM were associated with increased odds of recombinants in 2010–2015 (1.43 [1.35–1.51]). Subgroup analyses supported our main findings.DiscussionAs PWID, CSW, and MSM are associated with HIV-1 recombinants, increased preventative measures and HIV-1 molecular surveillance are crucial within these key populations.Systematic review registrationPROSPERO [CRD42017067164].

Published
2023
Full Text
View/download PDF

3. Approaches to STI Prevention and Control in a Highly Decentralized State: An Integrative Review

Author

Javier Gómez Castellá, Asunción Díaz Franco, Rosa Polo Rodríguez, and Julia del Amo Valero

Subjects
HIV, STI, Health policy, Strategic Plan, Spain, Reproduction, QH471-489, Medicine (General), R5-920
Abstract

The Spanish health system is highly decentralized and Autonomous Regions (AR) are responsible for managing and implementing the National Strategic Plan for Prevention and Control of HIV and other Sexually Transmitted Infections (STI) (2013–2020) via autonomous plans adapted to the characteristics of each region. The aim of this study is to report on actions taken to specifically address STI prevention and control in the autonomous plans within the mainframe of the National Strategic Plan. An integrative review was performed to analyse the health plans and HIV/STI plans of the Spanish AR during the period of validity of the current National Strategic Plan; 2013–2020. Plans were selected attending to specificity and whether strategies were in force during the year 2020. Our gatherings show that plans are largely focused to HIV prevention and control and, to a lesser extent, to STI prevention. The analysis on pre-existing resources for care of STI varied by region, and epidemiological surveillance systems for STI notification were not completely adopted by all of them. Particularly noteworthy are information campaigns, pre- and post-exposure prophylaxis for HIV, and prevention activities in community settings. The remarkable lack of studies concerning STI resources and investment in Spain highlights the necessity of consensus-based tools for evaluation and future planning of STI prevention and control measures. The high degree of heterogeneity among plans for prevention of HIV infection and STIs also points out a high number of different areas for improvement in the development of new AR plans in HIV/STI.

Published
2022
Full Text
View/download PDF

4. Epidemiologic Features and Control Measures during Monkeypox Outbreak, Spain, June 2022

Author

Rodriguez, Berta Suarez, Herrador, Bernardo R. Guzman, Franco, Asuncion Diaz, Farinas, Maria Paz Sanchez-Seco, Valero, Julia del Amo, Llorente, Adrian Hugo Aginagalde, Agreda, Juan Pablo Alonso Perez de, Malonda, Rosa Carbo, Castrillejo, Daniel, Lopez, Maria Dolores Chirlaque, Chong, Eduardo Javier Chong, Balbuena, Sonia Fernandez, Garcia, Virtudes Gallardo, Garcia-Cenoz, Manuel, Hernandez, Laura Garcia, Montalban, Elisa Gil, Carril, Fernando Gonzalez, Cortijo, Teresa Gonzalez, Bueno, Susana Jimenez, Sanchez, Aurora Limia, Dopido, Juan Antonio Linares, Lorusso, Nicola, Martins, Mario Margolles, Ochoa, Eva Maria Martinez, Mateo, Ana Martinez, Pena, Jacobo Mendioroz, Anton, Ana Isabel Negredo, Barros, Maria Teresa Otero, Martinez, Maria del Carmen Pacheco, Jimenez, Pilar Peces, Martin, Oscar-Guillermo Perez, Perez, Ana Isabel Rivas, Garcia, Maria Sastre, Soria, Fernando Simon, and Moros, Maria Jose Sierra

Subjects
Human monkeypox -- Statistics -- Control, Epidemics -- Statistics -- Control -- United Kingdom, Health
Abstract

During May-June 2022, after an alert notification initiated by the United Kingdom (1,2), >4,500 monkeypox cases had been confirmed worldwide, mainly in the European region (3-6). Chains of transmission without [...]

Published
2022
Full Text
View/download PDF

5. Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers

Author

Julia del Amo, Polo, Rosa, Moreno, Santiago, Berenguer, Juan, Martínez, Esteban, Hernán, Miguel, Martínez de Salazar, Pablo, García de Albéniz, Xabier, García-Albéniz, Xabier, Terán, Carolina, Morales, Miguel, Rial-Crestelo, David, Garcinuño, M. Angeles, García del Toro, Miguel, Hita, César, Gómez-Sirvent, Juan Luis, Buzón, Luis, Díaz de Santiago, Alberto, Arellano, Jose Pérez, Sanz, Jesus, Bachiller, Pablo, Alfaro, Elisa Martínez, Díaz-Brito, Vicente, Masiá, Mar, Hernández-Torres, Alicia, Guerra, Jose M., Santos, Jesús, Arazo, Piedad, Muñoz, Leopoldo, Arribas, Jose Ramon, Hernán, Miguel A., and Del Amo, Julia

Published
2023
Full Text
View/download PDF

6. Daily tenofovir disoproxil fumarate/emtricitabine and hydroxychloroquine for pre-exposure prophylaxis of COVID-19: a double-blind placebo-controlled randomized trial in healthcare workers

Author

Rosa Polo, Xabier García-Albéniz, Carolina Terán, Miguel Morales, David Rial-Crestelo, M. Angeles Garcinuño, Miguel García del Toro, César Hita, Juan Luis Gómez-Sirvent, Luis Buzón, Alberto Díaz de Santiago, Jose Pérez Arellano, Jesus Sanz, Pablo Bachiller, Elisa Martínez Alfaro, Vicente Díaz-Brito, Mar Masiá, Alicia Hernández-Torres, Jose M. Guerra, Jesús Santos, Piedad Arazo, Leopoldo Muñoz, Jose Ramon Arribas, Pablo Martínez de Salazar, Santiago Moreno, Miguel A. Hernán, Julia Del Amo, null Julia del Amo, Juan Berenguer, Esteban Martínez, Miguel Hernán, and Xabier García de Albéniz

Subjects
Microbiology (medical), SARS-CoV-2, Anti-HIV Agents, Adenine, Health Personnel, Organophosphonates, COVID-19, Pre-exposure prophylaxis, HIV Infections, General Medicine, Deoxycytidine, COVID-19 Drug Treatment, Infectious Diseases, Double-Blind Method, Humans, Emtricitabine, Pre-Exposure Prophylaxis, Randomized clinical trial, Tenofovir, Hydroxychloroquine
Abstract

To assess the effect of hydroxychloroquine (HCQ) and Tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) as pre-exposure prophylaxis on COVID-19 risk. EPICOS is a double-blind, placebo-controlled randomized trial conducted in Spain, Bolivia, and Venezuela. Healthcare workers with negative SARS-CoV-2 IgM/IgG test were randomly assigned to the following: daily TDF/FTC plus HCQ for 12 weeks, TDF/FTC plus HCQ placebo, HCQ plus TDF/FTC placebo, and TDF/FTC placebo plus HCQ placebo. Randomization was performed in groups of four. Primary outcome was laboratory-confirmed, symptomatic COVID-19. We also studied any (symptomatic or asymptomatic) COVID-19. We compared group-specific 14-week risks via differences and ratios with 95% CIs. Of 1002 individuals screened, 926 (92.4%) were eligible and there were 14 cases of symptomatic COVID-19: 220 were assigned to the TDF/FTC plus HCQ group (3 cases), 231 to the TDF/FTC placebo plus HCQ group (3 cases), 233 to the TDF/FTC plus HCQ placebo group (3 cases), and 223 to the double placebo group (5 cases). Compared with the double placebo group, 14-week risk ratios (95% CI) of symptomatic COVID-19 were 0.39 (0.00-1.98) for TDF + HCQ, 0.34 (0.00-2.06) for TDF, and 0.49 (0.00-2.29) for HCQ. Corresponding risk ratios of any COVID-19 were 0.51 (0.21-1.00) for TDF + HCQ, 0.81 (0.44-1.49) for TDF, and 0.73 (0.41-1.38) for HCQ. Adverse events were generally mild. The target sample size was not met. Our findings are compatible with both benefit and harm of pre-exposure prophylaxis with TDF/FTC and HCQ, alone or in combination, compared with placebo.

Published
2023
Full Text
View/download PDF

9. Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19

Author

Xabier, García-Albéniz, Julia, Del Amo, Rosa, Polo, José Miguel, Morales-Asencio, and Miguel A, Hernán

Subjects
COVID-19 Testing, SARS-CoV-2, Epidemiology, COVID-19, Humans, Hydroxychloroquine, Randomized Controlled Trials as Topic, COVID-19 Drug Treatment
Abstract

Recruitment into randomized trials of hydroxychloroquine (HCQ) for prevention of COVID-19 has been adversely affected by a widespread conviction that HCQ is not effective for prevention. In the absence of an updated systematic review, we conducted a meta-analysis of randomized trials that study the effectiveness of HCQ to prevent COVID-19.A search of PubMed, medRxiv, and clinicaltrials.gov combined with expert consultation found 11 completed randomized trials: 7 pre-exposure prophylaxis trials and 4 post-exposure prophylaxis trials. We obtained or calculated the risk ratio of COVID-19 diagnosis for assignment to HCQ versus no HCQ (either placebo or usual care) for each trial, and then pooled the risk ratio estimates.The pooled risk ratio estimate of the pre-exposure prophylaxis trials was 0.72 (95% CI: 0.58-0.90) when using either a fixed effect or a standard random effects approach, and 0.72 (95% CI: 0.55-0.95) when using a conservative modification of the Hartung-Knapp random effects approach. The corresponding estimates for the post-exposure prophylaxis trials were 0.91 (95% CI: 0.72-1.16) and 0.91 (95% CI: 0.62-1.35). All trials found a similar rate of serious adverse effects in the HCQ and no HCQ groups.A benefit of HCQ as prophylaxis for COVID-19 cannot be ruled out based on the available evidence from randomized trials. However, the "not statistically significant" findings from early prophylaxis trials were widely interpreted as definite evidence of lack of effectiveness of HCQ. This interpretation disrupted the timely completion of the remaining trials and thus the generation of precise estimates for pandemic management before the development of vaccines.

Published
2022
Full Text
View/download PDF

10. SARS-CoV-2 infection and coronavirus disease 2019 severity in persons with HIV on antiretroviral treatment

Author

Rosa Polo, Miguel A. Hernán, Inma Jarrín, Santiago Moreno, and Julia del Amo

Subjects
Coronavirus disease 2019 (COVID-19), business.industry, SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Immunology, Human immunodeficiency virus (HIV), COVID-19, HIV Infections, medicine.disease_cause, Virology, Article, Infectious Diseases, COVID-19 Testing, Anti-Retroviral Agents, Antiretroviral treatment, Immunology and Allergy, Medicine, Humans, business
Abstract

The relative susceptibility of people with HIV (PWH) to SARS-CoV-2 infection is debated. Numerous studies have been published with apparently contradictory findings but comparisons are difficult because they have been conducted in populations with different characteristics (e.g., age, prevalence of co-morbidities), they have used different comparison groups (e.g., HIV-negative cohorts, COVID-19 hospitalized patients, general population), and because of challenges to measure the most important confounders. Here, we review the evidence regarding risk and severity of SARS-CoV-2 infection in PWH compared with persons without HIV. Articles originate largely from high-income settings where the majority of the PWH are on ART. There was early evidence supporting higher frequency of SARS-CoV-2 testing in PWH but no evidence that, in PWH on ART, HIV infection increases susceptibility to SARS-CoV-2 infection, once confounding by socio-economic characteristic is taken into account and in spite of higher SARS-CoV-2 testing intensity. Most publications identify increased COVID-19 severity in PWH compared with people without HIV from the general population or compared with COVID-19 hospitalized patients. The only study with an ideal comparison group, the VACS, which minimizes confounding by design, has not, to date, identified differences in COVID-19 disease severity by HIV. Publications consistently identify that COVID-19 severity in PWH is not homogeneous and increases with age and baseline comorbidities. Because PWH have a higher prevalence of comorbidities than people without HIV, examining their respective contribution to poor health outcomes is not straight forward as they could mediate some or all the effect HIV may have on COVID-19 outcomes.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results